DOCSLIB.ORG

Penbutolol Sulfate Pentobarbital Calcium Pentoxyverine Citrate

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Penbutolol Sulfate Pentobarbital Calcium Pentoxyverine Citrate 1478 Infrared Reference Spectra JP XV Penbutolol Sulfate Preparation of sample: Paste method Pentobarbital Calcium Preparation of sample: Potassium bromide disk method Pentoxyverine Citrate Preparation of sample: Paste method JP XV Infrared Reference Spectra 1479 Pethidine Hydrochloride Preparation of sample: Potassium bromide disk method Phenethicillin Potassium Preparation of sample: Potassium bromide disk method L-Phenylalanine Preparation of sample: Potassium bromide disk method 1480 Infrared Reference Spectra JP XV Phytonadione Preparation of sample: Liquid film method Pindolol Preparation of sample: Potassium bromide disk method Pipemidic Acid Hydrate Preparation of sample: Potassium bromide disk method JP XV Infrared Reference Spectra 1481 Piperacillin Sodium Preparation of sample: Potassium bromide disk method Piperazine Adipate Preparation of sample: Potassium bromide disk method Piperazine Phosphate Hydrate Preparation of sample: Potassium bromide disk method 1482 Infrared Reference Spectra JP XV Pirenoxine Preparation of sample: Potassium bromide disk method Pirenzepine Hydrochloride Hydrate Preparation of sample: Potassium chloride disk method Piroxicam Preparation of sample: Potassium bromide disk method JP XV Infrared Reference Spectra 1483 Pivmecillinam Hydrochloride Preparation of sample: Potassium bromide disk method Potassium Canrenoate Preparation of sample: Potassium bromide disk method Potassium Clavulanate Preparation of sample: Potassium bromide disk method 1484 Infrared Reference Spectra JP XV Povidone Preparation of sample: Potassium bromide disk method Pranoprofen Preparation of sample: Potassium bromide disk method Pravastatin Sodium Preparation of sample: Potassium bromide disk method JP XV Infrared Reference Spectra 1485 Prazepam Preparation of sample: Potassium bromide disk method Prednisolone Preparation of sample: Potassium bromide disk method Prednisolone Acetate Preparation of sample: Potassium bromide disk method 1486 Infrared Reference Spectra JP XV Prednisolone Succinate Preparation of sample: Potassium bromide disk method Procaine Hydrochloride Preparation of sample: Potassium chloride disk method Procarbazine Hydrochloride Preparation of sample: Potassium chloride disk method JP XV Infrared Reference Spectra 1487 Procaterol Hydrochloride Hydrate Preparation of sample: Potassium bromide disk method Progesterone Preparation of sample: Potassium bromide disk method Proglumide Preparation of sample: Potassium bromide disk method 1488 Infrared Reference Spectra JP XV Promethazine Hydrochloride Preparation of sample: Potassium bromide disk method Propranolol Hydrochloride Preparation of sample: Potassium chloride disk method Propyl Parahydroxybenzoate Preparation of sample: Potassium bromide disk method JP XV Infrared Reference Spectra 1489 Protirelin Preparation of sample: Potassium bromide disk method Pyrantel Pamoate Preparation of sample: Potassium bromide disk method Pyrazinamide Preparation of sample: Potassium bromide disk method 1490 Infrared Reference Spectra JP XV Pyridoxine Hydrochloride Preparation of sample: Potassium chloride disk method Pyrrolnitrin Preparation of sample: Potassium bromide disk method Quinine Ethyl Carbonate Preparation of sample: Potassium bromide disk method JP XV Infrared Reference Spectra 1491 Quinine Sulfate Hydrate Preparation of sample: Potassium bromide disk method Ranitidine Hydrochloride Preparation of sample: Paste method Reserpine Preparation of sample: Potassium bromide disk method 1492 Infrared Reference Spectra JP XV Rifampicin Preparation of sample: Potassium bromide disk method Ritodrine Hydrochloride Preparation of sample: Potassium chloride disk method Rokitamycin Preparation of sample: Potassium bromide disk method JP XV Infrared Reference Spectra 1493 Roxatidine Acetate Hydrochloride Preparation of sample: Potassium chloride disk method Roxithromycin Preparation of sample: Potassium bromide disk method Saccharin Preparation of sample: Potassium bromide disk method 1494 Infrared Reference Spectra JP XV Saccharin Sodium Hydrate Preparation of sample: Potassium bromide disk method Salbutamol Sulfate Preparation of sample: Potassium bromide disk method Santonin Preparation of sample: Potassium bromide disk method JP XV Infrared Reference Spectra 1495 Scopolamine Butylbromide Preparation of sample: Potassium bromide disk method Siccanin Preparation of sample: Potassium bromide disk method Sodium Fusidate Preparation of sample: Potassium bromide disk method 1496 Infrared Reference Spectra JP XV Sodium Picosulfate Hydrate Preparation of sample: Potassium bromide disk method Sodium Polystyrene Sulfonate Preparation of sample: Potassium bromide disk method Sodium Prasterone Sulfate Hydrate Preparation of sample: Potassium bromide disk method JP XV Infrared Reference Spectra 1497 Sodium Salicylate Preparation of sample: Potassium bromide disk method Sodium Valproate Preparation of sample: Liquid film method Spiramycin Acetate Preparation of sample: Potassium bromide disk method 1498 Infrared Reference Spectra JP XV Spironolactone Preparation of sample: Potassium bromide disk method Sulbactam Sodium Preparation of sample: Potassium bromide disk method Sulbenicillin Sodium Preparation of sample: Potassium bromide disk method JP XV Infrared Reference Spectra 1499 Sulfadiazine Silver Preparation of sample: Paste method Sulfamethizole Preparation of sample: Potassium bromide disk method Sulfamethoxazole Preparation of sample: Potassium bromide disk method 1500 Infrared Reference Spectra JP XV Sulfamonomethoxine Hydrate Preparation of sample: Potassium bromide disk method Sulfinpyrazone Preparation of sample: Potassium bromide disk method Sulpiride Preparation of sample: Potassium bromide disk method JP XV Infrared Reference Spectra 1501 Sultamicillin Tosilate Hydrate Preparation of sample: Paste method Suxamethonium Chloride Hydrate Preparation of sample: Potassium bromide disk method Talampicillin Hydrochloride Preparation of sample: Potassium bromide disk method 1502 Infrared Reference Spectra JP XV Tamsulosin Hydrochloride Preparation of sample: Potassium chloride disk method Taurine Preparation of sample: Potassium bromide disk method Tegafur Preparation of sample: Potassium bromide disk method JP XV Infrared Reference Spectra 1503 Testosterone Propionate Preparation of sample: Potassium bromide disk method Tetracycline Hydrochloride Preparation of sample: Potassium chloride disk method Theophylline Preparation of sample: Potassium bromide disk method 1504 Infrared Reference Spectra JP XV Thiamine Chloride Hydrochloride Preparation of sample: Potassium bromide disk method Thiamylal Sodium Preparation of sample: Potassium bromide disk method Thioridazine Hydrochloride Preparation of sample: Potassium chloride disk method JP XV Infrared Reference Spectra 1505 L-Threonine Preparation of sample: Potassium bromide disk method Tiaramide Hydrochloride Preparation of sample: Potassium chloride disk method Ticlopidine Hydrochloride Preparation of sample: Potassium bromide disk method 1506 Infrared Reference Spectra JP XV Timepidium Bromide Hydrate Preparation of sample: Potassium bromide disk method Timolol Maleate Preparation of sample: Potassium bromide disk method Tinidazole Preparation of sample: Potassium bromide disk method JP XV Infrared Reference Spectra 1507 Tipepidine Hibenzate Preparation of sample: Potassium bromide disk method Tizanidine Hydrochloride Preparation of sample: Potassium chloride disk method Tocopherol Preparation of sample: Liquid film method 1508 Infrared Reference Spectra JP XV Tocopherol Acetate Preparation of sample: Liquid film method Tocopherol Calcium Succinate Preparation of sample: Liquid film method (measured as a solution of 0.08 g of Tocopherol Calcium Succinate in 0.2 mL of carbon tetrachloride) Tocopherol Nicotinate Preparation of sample: Liquid film method JP XV Infrared Reference Spectra 1509 Todralazine Hydrochloride Hydrate Preparation of sample: Potassium chloride disk method Tofisopam Preparation of sample: Potassium bromide disk method Tolazamide Preparation of sample: Potassium bromide disk method 1510 Infrared Reference Spectra JP XV Tolnaftate Preparation of sample: Potassium bromide disk method Tranexamic Acid Preparation of sample: Potassium bromide disk method Triamcinolone Preparation of sample: Potassium bromide disk method JP XV Infrared Reference Spectra 1511 Triamcinolone Acetonide Preparation of sample: Potassium bromide disk method Trichlormethiazide Preparation of sample: Potassium bromide disk method Triclofos Sodium Preparation of sample: Potassium bromide disk method 1512 Infrared Reference Spectra JP XV Trimebutine Maleate Preparation of sample: Potassium bromide disk method Trimetazidine Hydrochloride Preparation of sample: Potassium chloride disk method Trimethadione Preparation of sample: Solution method (measured as a solution in chloroform) JP XV Infrared Reference Spectra 1513 Trimetoquinol Hydrochloride Hydrate Preparation of sample: Potassium chloride disk method L-Tryptophan Preparation of sample: Potassium bromide disk method Tulobuterol Hydrochloride Preparation of sample: Potassium bromide disk method 1514 Infrared Reference Spectra JP XV Ubidecarenone Preparation of sample: Potassium bromide disk method Urapidil Preparation of sample: Potassium bromide disk method L-Valine Preparation of sample: Potassium bromide disk method JP XV Infrared Reference Spectra 1515 Vancomycin Hydrochloride Preparation of sample: Potassium bromide disk method Verapamil Hydrochloride Preparation of sample: Potassium chloride disk method Vinblastine Sulfate Preparation of sample: Potassium bromide disk method 1516 Infrared Reference Spectra JP XV Vincristine Sulfate Preparation of sample: Solution method (measured as a solution in chloroform) Voglibose Preparation of sample: Potassium bromide disk method Warfarin Potassium Preparation of sample: Potassium bromide disk method JP XV Infrared Reference Spectra 1517 Xylitol Preparation of sample: Potassium bromide disk method Zaltoprofen Preparation of sample: Potassium bromide disk method.
Load more

Recommended publications
  • Regasta-Tab-Leaflet-Pakistan
    50mg Tablets DESCRIPTION Investigations : Increased AST (SGOT), increased ALT (SGPT), increased γ-GTP, Regasta (Itopride HCl) is a prokinetic benzamide derivative. It inhibits dopamine and increased alkaline phosphatase and increased bilirubin. have a gastrokinetic effect. Chemically, Itopride HCl is N-[4-[2-(Dimethylamino) ethoxy]benzyl]-3,4- CONTRAINDICATIONS dimethoxybenzamide monohydrochloride. Its molecular formula is C20H26N2O4.HCl and Itopride HCl is contraindicated in: the structural formula is: - Patients with known hypersensitivity to itopride HCl or any of the excipient of the product. 0 - Patient s in whom an increase in gastrointestinal motility could be harmful e.g., gastrointestinal hemorrhage, mechanical obstruction or perforation. N CH3 PRECAUTIONS H3C H N HCI - Itopride HCl should be used with caution since it enhances the action of acetylcholine. 0 0 CH3 Also, caution is advised in treatment of patients suffering from Parkinson's disease and conditions involving dopamine regulation issues. 0 - Itopride HCl should not be used aimlessly for a long term when no improvement of H3C Itopride HCl gastrointestinal symptoms is observed. Pregnancy and Nursing Mothers QUALITATIVE & QUANTITATIVE COMPOSITION Itopride HCl should be used in pregnant women or in women who may possibly be Regasta (Itopride HCl) is available for oral administration as: pregnant only if the expected therapeutic benefits outweigh the possible risks associated with treatment. The safety of itopride HCl in pregnant women has not been established. Regasta Tablets 50mg It is ideal not to use itopride HCl in women during lactation, but if it is necessary, breast Each film-coated tablet contains: feeding should be avoided during the treatment of itopride HCl.
    [Show full text]
  • Comparative Evaluation of Dehydroepiandrosterone Sulfate
    Supplemental material to this article can be found at: http://dmd.aspetjournals.org/content/suppl/2016/12/01/dmd.116.072355.DC1 1521-009X/45/2/224–227$25.00 http://dx.doi.org/10.1124/dmd.116.072355 DRUG METABOLISM AND DISPOSITION Drug Metab Dispos 45:224–227, February 2017 Copyright ª 2017 by The American Society for Pharmacology and Experimental Therapeutics Short Communication Comparative Evaluation of Dehydroepiandrosterone Sulfate Potential to Predict Hepatic Organic Anion Transporting Polypeptide Transporter-Based Drug-Drug Interactions s Received July 4, 2016; accepted November 30, 2016 ABSTRACT Pharmacokinetic drug-drug interactions (DDIs) on hepatic organic 59 ml/rat. Comparison of the in vitro IC50 of rifampicin for DHEAS anion transporting polypeptides (OATPs) are important clinical issues. uptake by isolated rat hepatocytes and in vivo plasma rifampicin Previously, we reported that plasma dehydroepiandrosterone sulfate concentration suggested that the effect of rifampicin on the plasma Downloaded from (DHEAS) could serve as an endogenous probe to predict OATP-based DHEAS concentration was explained mostly by the inhibition of DDIs in monkeys using rifampicin as an OATP inhibitor. Since the hepatic OATPs, demonstrating that DHEAS could be a biomarker of contribution of hepatic OATPs to the changes in plasma DHEAS by hepatic OATP activity. Next, previously reported rifampicin-induced rifampicin remains unclear, however, we performed an in vivo phar- changes in plasma concentrations evaluated as an AUC ratio (AUCR) macokinetic study to explore this issue. Since plasma DHEAS of possible probe compounds were compared on the basis of concentrations were low in our rat model, the disposition of externally rifampicin dose/body surface area.
    [Show full text]
  • Isopropamide Iodide
    www.chemicalland21.com ISOPROPAMIDE IODIDE SYNONYMS (3-Carbamoyl-3,3-diphenylpropyl)diisopropylmethylammonium iodide; 2,2-Diphenyl-4- diisopropylaminobutyramide methiodide; 4-(Diisopropylamino)-2,2-diphenylbutyramide methiodide; gamma-(Aminocarbonyl)-N-methyl-N,N-bis(1-methylethyl)-gamma-phenylbenzenepropanaminium iodide; Iodure d'isopropamide; Ioduro de isopropamida; Isopropamide ioduro; Isopropamidi iodidum; Isoproponum iodide; PRODUCT IDENTIFICATION CAS RN 71-81-8 EINECS RN 200-766-8 FORMULA C23H33IN2O MOL WEIGHT 480.43 PHYSICAL AND CHEMICAL PROPERTIES PHYSICAL STATE white to off-white powder MELTING POINT 199 C BOILING POINT DENSITY SOLUBILITY IN WATER pH VAPOR DENSITY REFRACTIVE INDEX FLASH POINT GENERAL DESCRIPTION Isopropamide is a long-acting anticholinergic and antimuscarinic drug of quaternary ammonium structure. It is used in the form of the iodide, (also bromide or chloride) to treat peptic ulcer and to suppress gastric secretion other gastrointestinal disorders. Brands of Isopropamide drugs: Darbid Dipramide Isamide Marygin-M Piaccamide Priamide Priazimide Sanulcin Tyrimide Quaternary ammonium anticholinergics (Synthetic) ATC Code Product CAS RN. A03AB01 Benzilonium bromide 1050-48-2 A03AB02 Glycopyrrolate 596-51-0 A03AB03 Oxyphenonium 14214-84-7 A03AB04 Penthienate 22064-27-3 A03AB05 Propantheline 50-34-0 A03AB06 Otilonium bromide 26095-59-0 A03AB07 Methantheline 5818-17-7 Please mail us if you want to sell your product or need to buy some products) www.chemicalland21.com ISOPROPAMIDE IODIDE A03AB08 Tridihexethyl 60-49-1 A03AB09 Isopropamide 7492-32-2 A03AB10 Hexocyclium 6004-98-4 A03AB11 Poldine 596-50-9 A03AB12 Mepenzolic acid 25990-43-6 A03AB13 Bevonium 33371-53-8 A03AB14 Pipenzolate 13473-38-6 A03AB15 Diphemanil methylsulfate 62-97-5 A03AB16 (2-Benzhydryloxyethyl)diethyl-methylammonium iodide A03AB17 Tiemonium iodide 144-12-7 A03AB18 Prifinium bromide 4630-95-9 A03AB19 Timepidium bromide 35035-05-3 A03AB21 Fenpiverinium bromide 125-60-0 03AB53 Oxyphenonium, combinations STABILITY AND REACTIVITY STABILITY Stable under normal conditions.
    [Show full text]
  • Drug Class Review Beta Adrenergic Blockers
    Drug Class Review Beta Adrenergic Blockers Final Report Update 4 July 2009 Update 3: September 2007 Update 2: May 2005 Update 1: September 2004 Original Report: September 2003 The literature on this topic is scanned periodically. The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage guidelines, nor should they be read as an endorsement of, or recommendation for, any particular drug, use, or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports. Mark Helfand, MD, MPH Kim Peterson, MS Vivian Christensen, PhD Tracy Dana, MLS Sujata Thakurta, MPA:HA Drug Effectiveness Review Project Marian McDonagh, PharmD, Principal Investigator Oregon Evidence-based Practice Center Mark Helfand, MD, MPH, Director Oregon Health & Science University Copyright © 2009 by Oregon Health & Science University Portland, Oregon 97239. All rights reserved. Final Report Update 4 Drug Effectiveness Review Project TABLE OF CONTENTS INTRODUCTION .......................................................................................................................... 6 Purpose and Limitations of Evidence Reports........................................................................................ 8 Scope and Key Questions .................................................................................................................... 10 METHODS.................................................................................................................................
    [Show full text]
  • WITHOUTUS010307409B2 (12 ) United States Patent ( 10 ) Patent No
    WITHOUTUS010307409B2 (12 ) United States Patent ( 10 ) Patent No. : US 10 , 307 ,409 B2 Chase et al. (45 ) Date of Patent: Jun . 4 , 2019 ( 54 ) MUSCARINIC COMBINATIONS AND THEIR (52 ) U . S . CI. USE FOR COMBATING CPC . .. .. A61K 31/ 4439 (2013 . 01 ) ; A61K 9 /0056 HYPOCHOLINERGIC DISORDERS OF THE (2013 . 01 ) ; A61K 9 / 7023 ( 2013 . 01 ) ; A61K CENTRAL NERVOUS SYSTEM 31 / 166 ( 2013 . 01 ) ; A61K 31 / 216 ( 2013 . 01 ) ; A61K 31 /4178 ( 2013 .01 ) ; A61K 31/ 439 (71 ) Applicant: Chase Pharmaceuticals Corporation , ( 2013 .01 ) ; A61K 31 /44 (2013 . 01 ) ; A61K Washington , DC (US ) 31/ 454 (2013 .01 ) ; A61K 31/ 4725 ( 2013 .01 ) ; A61K 31 /517 (2013 .01 ) ; A61K 45 / 06 ( 72 ) Inventors : Thomas N . Chase , Washington , DC (2013 . 01 ) (US ) ; Kathleen E . Clarence -Smith , ( 58 ) Field of Classification Search Washington , DC (US ) CPC .. A61K 31/ 167 ; A61K 31/ 216 ; A61K 31/ 439 ; A61K 31 /454 ; A61K 31 /4439 ; A61K (73 ) Assignee : Chase Pharmaceuticals Corporation , 31 /4175 ; A61K 31 /4725 Washington , DC (US ) See application file for complete search history. ( * ) Notice : Subject to any disclaimer, the term of this (56 ) References Cited patent is extended or adjusted under 35 U . S . C . 154 (b ) by 0 days . U . S . PATENT DOCUMENTS 5 ,534 ,520 A 7 / 1996 Fisher et al. ( 21) Appl . No. : 15 /260 , 996 2008 /0306103 Al 12 /2008 Fisher et al. 2011/ 0021503 A1* 1/ 2011 Chase . .. A61K 31/ 27 ( 22 ) Filed : Sep . 9 , 2016 514 / 215 2011/ 0071135 A1 * 3 / 2011 Chase . .. .. .. A61K 31/ 166 (65 ) Prior Publication Data 514 / 215 2011 /0245294 Al 10 / 2011 Paborji et al.
    [Show full text]
  • Comparative Study of Different Doses of Rocuronium Bromide For
    MedDocs Publishers Annals of Anesthesia and Pain Medicine Open Access | Research Article Comparative study of different doses of rocuronium bromide for endotracheal intubation Nidhi V Sardhara1*; Sonal A Shah2; Dhaval P Pipaliya3; Shivansh Gupta3 1SVP hospital, 13th floor, Room no 13125, Near Ellis bridge, Ahmedabad, Gujarat-380006 2Assistant Professor, Department of anesthesia, Smt. NHL Municipal Medical College, Ahmedabad, Gujarat, India 3First year Resident, Department of anesthesia, Smt. NHL Municipal Medical College, Ahmedabad, Gujarat, India *Corresponding Author(s): Nidhi V Sardhara Abstract SVP hospital, 13th floor, Room no 13125, Near Ellis Background: Endotracheal intubation is one of such bridge, Ahmedabad, Gujarat-380006 development without which general anesthesia cannot be Tel: +91-9428-44-7878, Fax: 7926-57-8452 considered safe for any major surgery particularly head and Email: [email protected] neck, thoracic and abdominal surgeries. Ever since the ad- vent of anesthesia, anesthesiologists have been in search of an ideal muscle relaxants which can provide ideal intu- bating conditions in ultrashort duration with minimal side effects. Rocuronium bromide provides fast onset of action, Received: Mar 11, 2020 an intermediate duration of action and rapid recovery, good Accepted: Apr 24, 2020 to excellent intubating conditions at doses having minimal Published Online: Apr 30, 2020 or no haemodynamic changes. Present study is to compare the effect of different doses (0.6 mg/kg, 0.9 mg/kg, 1.2 mg/ Journal: Annals of Anesthesia and Pain Medicine kg) of Rocuronium bromide for endotracheal intubation at Publisher: MedDocs Publishers LLC 60 seconds. Online edition: http://meddocsonline.org/ Material and methods: This study was carried out by Copyright: © Sardhara NV (2020).
    [Show full text]
  • Alpha^ and Beta^Blocking Agents: Pharmacology and Properties
    CURRENT DRUG THERAPY DONALD G. VIDT, MD AND ALAN BAKST, PharmD, EDITORS Alpha^ and beta^blocking agents: pharmacology and properties PROFESSOR B.N.C. PRICHARD • Adrenergic receptors have been separated into alpha and beta groups, which have then been further subdivided. Agents have been developed that block each type of receptor with varying degrees of specificity between the sub-types, leading to differences in pharmacodynamic profile. A more recent innovation has been the development of multiple action beta-blocking drugs, ie, those not only blocking the beta receptors but also posessing a peripheral vasodilator effect that may be due to alpha blockade, beta-2 stimulation, or a vasodilator action independent of either alpha or beta receptors. • INDEX TERMS: ALPHA BLOCKERS; BETA BLOCKERS; HYPERTENSION • CLEVE CLIN ] MED 1991; 58:33 7-350 HE CONCEPT that binding of Rosenblueth suggested that a transmitter released at catecholamines to receptors leads to differ- sympathetic nerve endings produced either inhibitory ing responses was first described by Langley, or excitatory responses as a result of combination with who in 1905 noted that a cell may make sympathin I or sympathin E at the receptor.3 Tmotor or inhibitory substances or both, and that "the The current classification of alpha and beta respon- effect of a nerve impulse depends upon the proportion ses is based on the classic work of Ahlquist,4 who of the two kinds of receptive substance which is af- studied six sympathomimetic amines and found two fected by the impulse."1 In 1906, Dale reported that patterns of reactivity. One group of actions, mediated ergot blocked the excitatory but not the inhibitory ac- by what were termed "alpha receptors," were principally tions of adrenaline.2 In 1933, Cannon and excitatory.
    [Show full text]
  • Muscarinic Acetylcholine Receptor
    mAChR Muscarinic acetylcholine receptor mAChRs (muscarinic acetylcholine receptors) are acetylcholine receptors that form G protein-receptor complexes in the cell membranes of certainneurons and other cells. They play several roles, including acting as the main end-receptor stimulated by acetylcholine released from postganglionic fibersin the parasympathetic nervous system. mAChRs are named as such because they are more sensitive to muscarine than to nicotine. Their counterparts are nicotinic acetylcholine receptors (nAChRs), receptor ion channels that are also important in the autonomic nervous system. Many drugs and other substances (for example pilocarpineand scopolamine) manipulate these two distinct receptors by acting as selective agonists or antagonists. Acetylcholine (ACh) is a neurotransmitter found extensively in the brain and the autonomic ganglia. www.MedChemExpress.com 1 mAChR Inhibitors & Modulators (+)-Cevimeline hydrochloride hemihydrate (-)-Cevimeline hydrochloride hemihydrate Cat. No.: HY-76772A Cat. No.: HY-76772B Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic receptor agonist, is a candidate therapeutic drug for receptor agonist, is a candidate therapeutic drug for xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR The general pharmacol. properties of this drug on the The general pharmacol. properties of this drug on the gastrointestinal, urinary, and reproductive systems and other… gastrointestinal, urinary, and reproductive systems and other… Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 1 mg, 5 mg 1 mg, 5 mg AC260584 Aclidinium Bromide Cat. No.: HY-100336 (LAS 34273; LAS-W 330) Cat.
    [Show full text]
  • The In¯Uence of Medication on Erectile Function
    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
    [Show full text]
  • Allergy Testing and History Form
    Skin Testing Information and Consent 1. Skin Testing An allergy skin test is used to identify the substances that are causing your allergy symptoms. We will apply several extracts of common allergens to the skin and observe for a reaction. The reactions are then graded and confirmatory intradermal testing may be performed. This involves placing a small amount of extract under the skin of the upper arm. We then observe the reaction and record the results. On the day of testing please wear a short-sleeved shirt that can be pushed up comfortably to your shoulder. Allow 1-2 hours for your test session. You will need to stay on the premises during this time. Please do not bring children to your appointment. 2. Risks of Skin Testing Bleeding and infection may occur due to abrading of the skin. Any time the skin integrity is broken it puts on at risk for infection. However, this is a rare occurrence. The antigens used for testing are sterile and approved by the FDA. Occasionally, skin testing can trigger a severe allergic reaction requiring treatment with medications and/or treatment in the ER. Patients with asthma are at increased risk for triggering an asthma attack during testing. You should not undergo testing if you feel that you have allergy or asthma symptoms are currently under poor control. 3. Contraindications to Skin Testing Women who are pregnant or anyone who is currently taking Beta-Blockers, Tricyclic Anti-depressants or MAOI’s medications will NOT be skin tested. Please be sure to inform us of ALL your medications before the skin test is applied.
    [Show full text]
  • Sodium Prasterone Sulfate Hydrate Sodium Pyrosulfite
    JP XVI Official Monographs / Sodium Pyrosulfite 1411 50 mL. Perform the test using this solution as the test solu- Sodium Prasterone Sulfate Hydrate tion. Prepare the control solution as follows: to 0.40 mL of 0.005 mol/L sulfuric acid VS add 20 mL of acetone, 1 mL of プラステロン硫酸エステルナトリウム水和物 dilute hydrochloric acid and water to make 50 mL (not more than 0.032z). (4) Heavy metals <1.07>—Proceed with 2.0 g of Sodium Prasterone Sulfate Hydrate according to Method 2, and per- form the test. Prepare the control solution with 2.0 mL of Standard Lead Solution (not more than 10 ppm). (5) Related substances—Dissolve 0.10 g of Sodium Prasterone Sulfate Hydrate in 10 mL of methanol, and use C19H27NaO5S.2H2O: 426.50 this solution as the sample solution. Pipet 1 mL of the sam- Monosodium 17-oxoandrost-5-en-3b-yl sulfate dihydrate ple solution, add methanol to make exactly 200 mL, and use [1099-87-2, anhydride] this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatogra- Sodium Prasterone Sulfate Hydrate contains not phy <2.03>. Spot 5 mL each of the sample solution and stand- less than 98.0z of sodium prasterone sulfate ard solution on a plate of silica gel with fluorescent indicator (C19H27NaO5S: 390.47), calculated on the dried basis. for thin-layer chromatography. Develop the plate with a mixture of chloroform, methanol and water (75:22:3) to a Description Sodium Prasterone Sulfate Hydrate occurs as distance of about 10 cm, and air-dry the plate.
    [Show full text]
  • Reproductive DHEA-S
    Reproductive DHEA-S Analyte Information - 1 - DHEA-S Introduction DHEA-S, DHEA sulfate or dehydroepiandrosterone sulfate, it is a metabolite of dehydroepiandrosterone (DHEA) resulting from the addition of a sulfate group. It is the sulfate form of aromatic C19 steroid with 10,13-dimethyl, 3-hydroxy group and 17-ketone. Its chemical name is 3β-hydroxy-5-androsten-17-one sulfate, its summary formula is C19H28O5S and its molecular weight (Mr) is 368.5 Da. The structural formula of DHEA-S is shown in (Fig.1). Fig.1: Structural formula of DHEA-S Other names used for DHEA-S include: Dehydroisoandrosterone sulfate, (3beta)-3- (sulfooxy), androst-5-en-17-one, 3beta-hydroxy-androst-5-en-17-one hydrogen sulfate, Prasterone sulfate and so on. As DHEA-S is very closely connected with DHEA, both hormones are mentioned together in the following text. Biosynthesis DHEA-S is the major C19 steroid and is a precursor in testosterone and estrogen biosynthesis. DHEA-S originates almost exclusively in the zona reticularis of the adrenal cortex (Fig.2). Some may be produced by the testes, none is produced by the ovaries. The adrenal gland is the sole source of this steroid in women, whereas in men the testes secrete 5% of DHEA-S and 10 – 20% of DHEA. The production of DHEA-S and DHEA is regulated by adrenocorticotropin (ACTH). Corticotropin-releasing hormone (CRH) and, to a lesser extent, arginine vasopressin (AVP) stimulate the release of adrenocorticotropin (ACTH) from the anterior pituitary gland (Fig.3). In turn, ACTH stimulates the adrenal cortex to secrete DHEA and DHEA-S, in addition to cortisol.
    [Show full text]